Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Reaffirms Lupin’s commitment to sustainable resource management
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
PICCOLO trial met its primary endpoint of objective response rate (ORR)
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
Subscribe To Our Newsletter & Stay Updated
